[go: up one dir, main page]

DE60310400D1 - Botulinustoxine zur behandlung von priapismus - Google Patents

Botulinustoxine zur behandlung von priapismus

Info

Publication number
DE60310400D1
DE60310400D1 DE60310400T DE60310400T DE60310400D1 DE 60310400 D1 DE60310400 D1 DE 60310400D1 DE 60310400 T DE60310400 T DE 60310400T DE 60310400 T DE60310400 T DE 60310400T DE 60310400 D1 DE60310400 D1 DE 60310400D1
Authority
DE
Germany
Prior art keywords
priapism
toxine
botulinus
treatment
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60310400T
Other languages
English (en)
Other versions
DE60310400T2 (de
Inventor
K Naumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60310400D1 publication Critical patent/DE60310400D1/de
Application granted granted Critical
Publication of DE60310400T2 publication Critical patent/DE60310400T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60310400T 2002-06-26 2003-06-24 Botulinustoxine zur behandlung von priapismus Expired - Lifetime DE60310400T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US183221 1994-01-14
US10/183,221 US6776991B2 (en) 2002-06-26 2002-06-26 Methods for treating priapism
PCT/US2003/019922 WO2004002502A1 (en) 2002-06-26 2003-06-24 Botulinum toxins for treating priapism

Publications (2)

Publication Number Publication Date
DE60310400D1 true DE60310400D1 (de) 2007-01-25
DE60310400T2 DE60310400T2 (de) 2007-10-11

Family

ID=29779076

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310400T Expired - Lifetime DE60310400T2 (de) 2002-06-26 2003-06-24 Botulinustoxine zur behandlung von priapismus

Country Status (10)

Country Link
US (1) US6776991B2 (de)
EP (1) EP1515735B1 (de)
JP (3) JP4602762B2 (de)
AT (1) ATE347898T1 (de)
AU (1) AU2003243770B2 (de)
BR (1) BR0312099A (de)
CA (1) CA2489239C (de)
DE (1) DE60310400T2 (de)
ES (1) ES2278196T3 (de)
WO (1) WO2004002502A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364586B2 (en) 2001-12-21 2008-04-29 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO2004010934A2 (en) * 2002-07-29 2004-02-05 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US20070240454A1 (en) 2006-01-30 2007-10-18 Brown David P Method and apparatus for continuous or batch optical fiber preform and optical fiber production
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US20070283969A1 (en) * 2006-06-12 2007-12-13 Medtronic Vascular, Inc. Method of Diagnosing and Treating Erectile Dysfunction
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP4166107A1 (de) 2008-05-09 2023-04-19 Nuvaira, Inc. Systeme, anordnungen und verfahren zur behandlung eines bronchialbaums
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
CN102639077B (zh) 2009-10-27 2015-05-13 赫莱拉公司 具有可冷却的能量发射组件的递送装置
EP2498705B1 (de) 2009-11-11 2014-10-15 Holaira, Inc. Vorrichtung zur gewebebehandlung und stenosekontrolle
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69435302D1 (de) 1993-12-28 2010-08-26 Allergan Inc Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
US5562899A (en) * 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
CN1480212B (zh) * 1997-07-15 2013-12-04 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6376460B2 (en) * 1998-08-07 2002-04-23 Flinders Technologies Pty. Ltd. Method of modulating cellular activity
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SG99857A1 (en) * 1999-11-18 2003-11-27 Univ Singapore A method of treatment and prophylaxis
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP4602752B2 (ja) * 2004-01-14 2010-12-22 帝人株式会社 撚糸、撚糸の製造方法および撚糸の製造装置

Also Published As

Publication number Publication date
CA2489239A1 (en) 2004-01-08
BR0312099A (pt) 2005-03-29
ES2278196T3 (es) 2007-08-01
US6776991B2 (en) 2004-08-17
AU2003243770B2 (en) 2007-03-22
JP2005533819A (ja) 2005-11-10
CA2489239C (en) 2011-10-11
JP4602762B2 (ja) 2010-12-22
WO2004002502A1 (en) 2004-01-08
EP1515735A1 (de) 2005-03-23
DE60310400T2 (de) 2007-10-11
US20040001865A1 (en) 2004-01-01
ATE347898T1 (de) 2007-01-15
JP2013166792A (ja) 2013-08-29
EP1515735B1 (de) 2006-12-13
JP2010222367A (ja) 2010-10-07
AU2003243770A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
DK1558279T3 (da) Botulinumtoksin til behandling af ulcus pepticum og gastroesophageal reflux-sygdom
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TW200503751A (en) Methods for treating sinus headache
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
MY151032A (en) Treatment of tnf? related disorders
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
DE60005688D1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
MEP31508A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20063300L (no) Fremgangsmater for behandling av akutt inflammasjon i dyr med p38 MAP kinaseinhibitorer
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
TW200507840A (en) Method of treating multiple myeloma
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
BR0302037B1 (pt) método e aparelho de tratamento de costura.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl

Legal Events

Date Code Title Description
8364 No opposition during term of opposition